Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

China flag China · Delayed Price · Currency is CNY
55.89
-1.10 (-1.93%)
Jun 16, 2026, 3:00 PM CST
Market Cap22.81B -21.3%
Revenue (ttm)3.82B +29.7%
Net Income1.01B +15.1%
EPS2.47 +14.3%
Shares Out 408.19M
PE Ratio22.65
Forward PE17.88
Dividend0.62 (1.09%)
Ex-Dividend DateMay 29, 2026
Volume4,332,973
Open56.66
Previous Close56.99
Day's Range55.08 - 56.66
52-Week Range53.05 - 93.52
Beta-0.14
AnalystsStrong Buy
Price Target76.00 (+35.98%)
Earnings DateAug 21, 2026

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, including pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 3,644
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688278
Full Company Profile

Financial Performance

In 2025, Xiamen Amoytop Biotech's revenue was 3.70 billion, an increase of 31.18% compared to the previous year's 2.82 billion. Earnings were 1.03 billion, an increase of 24.61%.

Financial Statements